Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.

Launched by RENJI HOSPITAL · Aug 24, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new anesthetic called Ciprofol, which is being tested for use during gastrointestinal endoscopy procedures in obese patients. Ciprofol works similarly to another anesthetic called propofol but is effective at much lower doses. Early results suggest that Ciprofol may cause less pain during injection and fewer issues with breathing and circulation compared to propofol. The goal of the trial is to find the right dose of Ciprofol that will keep patients comfortable during these important procedures, especially for those who are obese.

To be eligible for this study, participants should be between the ages of 18 and 60, have a body mass index (BMI) of 28 or higher, and be scheduled for routine gastrointestinal endoscopy. They should also be in generally good health, as defined by a specific medical classification. Participants will be asked to provide informed consent, meaning they understand the study and agree to take part in it voluntarily. If you join the trial, you can expect to receive the new anesthetic during your procedure and help researchers learn more about its safety and effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age, ≤18 and ≤60 years, no gender limit
• • 2. Undergoing routine gastrointestinal endoscopic diagnosis and treatment
• • 3. American Society of Anesthesiologists (ASA) classification I-II
• • 4. Body Mass Index(BMI) ≥28kg/m\^2
• • 5. Clearly understand and voluntarily participate in the study; provide signed informed consent
• Exclusion Criteria:
• • 1. Unhealthy alcohol drinking, defined by more than three standard drinks per day (≈10 g alcohol , equivalent to 50 g of strong Chinese spirits)
• • 2. Drug abuse history within 3 months before the screening period
• • 3. People who are known to be allergic to eggs, bean products, opioids and other drugs, propofol, etc
• • 4. The researcher believes that patients should not participate in this trial